论文部分内容阅读
目的:探讨阿莫西林克拉维酸钾与雷贝拉唑钠联合治疗儿童幽门螺杆菌阳性胃病的临床疗效及安全性。方法:选取2011年1月-2012年1月我院收治的幽门螺杆菌阳性胃病患儿45例,随机分为对照组(25例)与观察组(20例),分别实施奥美拉唑+阿莫西林+克拉霉素传统三联疗法,与阿莫西林克拉维酸钾+雷贝拉唑钠+克拉霉素10d序贯疗法,观察两组的临床疗效。结果:观察组的治疗有效率及Hp清除率均明显高于对照组(96%VS75%,92%VS70%),且不良反应发生率明显低于对照组(8%VS25%),P<0.05,有统计学意义。结论:阿莫西林克拉维酸钾+雷贝拉唑钠联合治疗儿童幽门螺杆菌阳性胃病疗效确切,Hp清除率高,不良反应少,安全可靠,值得推广。
Objective: To investigate the clinical efficacy and safety of amoxicillin-clavulanate potassium combined with rabeprazole sodium in the treatment of Helicobacter pylori positive gastropathy in children. Methods: From January 2011 to January 2012, 45 children with Helicobacter pylori positive gastropathy admitted to our hospital were randomly divided into control group (n = 25) and observation group (n = 20), and received omeprazole + Amoxicillin + clarithromycin traditional triple therapy, and amoxicillin potassium clavulanate + rabeprazole sodium clarithromycin 10d sequential therapy, the clinical efficacy of the two groups were observed. Results: The treatment efficiency and Hp clearance rate in the observation group were significantly higher than those in the control group (96% VS75%, 92% VS70%), and the incidence of adverse reactions was significantly lower than that of the control group (8% VS25%), P <0.05 , With statistical significance. Conclusion: Combination of amoxicillin and clavulanate potassium plus rabeprazole sodium in the treatment of positive Helicobacter pylori infection in children is effective, high rate of Hp clearance, few adverse reactions, safe and reliable, and worth to be popularized.